The lead investigator of the study from the Children's Oncology Group said the findings represent a new standard of care. Children with a first relapse of B-cell acute lymphoblastic leukemia (B-ALL) ...
KMT2A-rearranged acute lymphoblastic leukemia (ALL) in infants is an aggressive disease with 3-year event-free survival below 40%. Most relapses occur during treatment, with two thirds occurring ...
In a recent study, Blincyto (blinatumomab) had longer survival rates than standard chemotherapy for certain patients with ALL. For patients with Philadelphia chromosome—negative (Ph-) relapsed or ...
This study aims to evaluate the safety, feasibility, effectiveness, and cost-saving potential of a shortened, vial-sharing outpatient blinatumomab regimen for treating relapsed or refractory (R/R) ALL ...
Adding blinatumomab to consolidation chemotherapy for B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in patients without measurable residual disease (MRD) led to improvements in overall and ...
At the recent 2019 American Society of Hematology annual meeting, researchers confirmed a clinical benefit for blinatumomab (Blincyto) in children and young adults with B-cell acute lymphoblastic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results